ADMA Biologics Inc (NASDAQ:ADMA) Major Shareholder Acquires $1,050,000.00 in Stock

ADMA Biologics Inc (NASDAQ:ADMA) major shareholder Perceptive Advisors Llc bought 500,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The stock was bought at an average cost of $2.10 per share, with a total value of $1,050,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Tuesday, February 11th, Perceptive Advisors Llc bought 4,563,700 shares of ADMA Biologics stock. The stock was bought at an average cost of $3.50 per share, with a total value of $15,972,950.00.

Shares of ADMA opened at $2.98 on Thursday. ADMA Biologics Inc has a 1 year low of $1.45 and a 1 year high of $6.31. The company has a current ratio of 6.12, a quick ratio of 2.33 and a debt-to-equity ratio of 3.23. The stock has a 50 day simple moving average of $3.05 and a 200-day simple moving average of $4.08. The stock has a market cap of $248.69 million, a PE ratio of -3.31 and a beta of 2.81.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). ADMA Biologics had a negative net margin of 164.50% and a negative return on equity of 167.18%. The business had revenue of $12.04 million for the quarter, compared to analyst estimates of $11.92 million. On average, sell-side analysts forecast that ADMA Biologics Inc will post -0.5 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ADMA. Rhumbline Advisers increased its holdings in ADMA Biologics by 55.9% during the 3rd quarter. Rhumbline Advisers now owns 45,841 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 16,443 shares in the last quarter. Voya Investment Management LLC increased its holdings in ADMA Biologics by 60.4% during the 3rd quarter. Voya Investment Management LLC now owns 18,688 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 7,038 shares in the last quarter. State Street Corp increased its holdings in ADMA Biologics by 75.5% during the 3rd quarter. State Street Corp now owns 696,404 shares of the biotechnology company’s stock valued at $3,099,000 after purchasing an additional 299,511 shares in the last quarter. Phoenix Holdings Ltd. acquired a new stake in ADMA Biologics during the 3rd quarter valued at $144,000. Finally, California State Teachers Retirement System increased its holdings in ADMA Biologics by 86.3% during the 3rd quarter. California State Teachers Retirement System now owns 78,426 shares of the biotechnology company’s stock valued at $349,000 after purchasing an additional 36,333 shares in the last quarter. 54.73% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on ADMA. ValuEngine raised ADMA Biologics from a “sell” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright dropped their target price on ADMA Biologics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 16th. Finally, BidaskClub cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $10.00.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: How to Invest in Growth Stocks

Insider Buying and Selling by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.